Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Amgen To Acquire Turkish Drug Firm
by Lisa M. Jarvis
April 30, 2012
| A version of this story appeared in
Volume 90, Issue 18
Amgen has agreed to pay $700 million for Turkey-based Mustafa Nevzat Pharmaceuticals. Privately held Mustafa Nevzat, which had sales of roughly $200 million in 2011, is a leading supplier of drugs to Turkish hospitals. Like many of its big pharma competitors, Amgen has been pushing into emerging markets; last year, it paid $215 million for the Brazilian generic drug firm Bergamo. Amgen established a Turkish affiliate in 2010 that markets two products in the country.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter